VITO Health and the Center for Proteomics at the University of Antwerp built strong expertise in mass spectrometry-based peptide analysis. Building on this expertise, Prof. Geert Baggerman and his team developed a state-of-the-art MS-based immuno-peptidomics platform to support biotech and biopharma companies in immunotherapy development.
I was asked to screen industry interest in this MS-based immuno-peptidomics service platform in the immunotherapy and adoptive cell therapy market. I interviewed relevant SMEs and large biotech companies across Europe to validate market appetite and early adopter interest.
I also estimated the business potential, developed pricing and potential business models, mapped the competitive landscape of service providers and the IP landscape, and calculated the financial needs to build a professional service platform.
The spin-off ImmuneSpec has since been founded.
